MedTrace Logo

Dose-Ranging Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00098228 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 686

Last updated 2011-10-25

No results posted yet for this study

Summary

The trial is designed to identify an appropriate dose of QAB149 for delivery via a multiple dose inhaler for use in the COPD Phase III program.

Conditions

Interventions

DRUG

QAB149

Sponsors & Collaborators

Principal Investigators

  • Novartis East Hanover · 862-778-8300

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2004-12-31
Completion
2004-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00098228 on ClinicalTrials.gov